Experienced in WT1-Related Wilms Tumor Syndromes

Jordi G. Esteve

Barcelona, CT, ES 
Experienced in WT1-Related Wilms Tumor Syndromes
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Jordi Esteve practices in Barcelona, Spain. Esteve is rated as an Experienced expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Their top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Graft.

Their clinical research consists of co-authoring 251 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of WT1-Related Wilms Tumor Syndromes.

Locations

Barcelona, CT 08036, Spain
Other Locations
Madrid, MD, Spain
Badalona, CT 08916, Spain
Valencia, VC, Spain
Bellaterra, CT 08193, Spain
Zaragoza, AR 50009, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase 2 Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity (A3B1) Conjugated With the Co-stimulatory Regions 4-1BB and CD3z (ARI-0001 Cells) in Patients With CD19+ Acute Lymphoid Leukemia Resistant or Refractory to Therapy
Phase 2 Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity (A3B1) Conjugated With the Co-stimulatory Regions 4-1BB and CD3z (ARI-0001 Cells) in Patients With CD19+ Acute Lymphoid Leukemia Resistant or Refractory to Therapy
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drug: ARI-0001 cells
Study Phase: Phase 2

251 Total Publications

Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.
Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.
Journal: International journal of molecular sciences
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Esteve's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile